Oruka Therapeutics announces $500M common stock, warrants offering

Oruka Therapeutics (ORKA) announced that it has commenced an underwritten public offering of $500M of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares of common stock and pre-funded warrants are being offered by Oruka. Leerink Partners, TD Cowen, Goldman Sachs & Co., Stifel and Guggenheim Securities are acting as joint bookrunning managers for the proposed offering. LifeSci Capital is acting as passive bookrunning manager for the proposed offering.